NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its third-quarter 2009 revenues decreased around 2 percent, but were up approximately 5 percent excluding the negative impact of foreign currency translation.
The Franklin Lakes, NJ-based medical devices, diagnostics, and life sciences products firm generated total revenues of $1.82 billion for the three-month period ended June 30 compared to revenues of $1.85 billion for the second quarter of 2008.
Its BD Medical segment had revenues of $968.7 million, down 3 percent from $998.1 million. Its BD Diagnostics segment had revenues of $566.4 million, up 2 percent from $553.4 million.
BD Biosciences' revenue declined 4 percent to $285.2 million from $297.8 million. The firm said that excluding foreign currency impact the segment declined 1 percent. "Demand in the US for capital equipment in the research and clinical segments continued to be impacted by funding constraints," BD said in a statement.
The firm posted a profit of $341 million, or $1.39 per share, up from $297.1 million, or $1.18 per share, the year before. Its R&D expenses declined less than 2 percent to $98.5 million from $99.9 million, and its SG&A spending declined around 1 percent to $429.9 million from $435.8 million.
BD did not provide its cash position as of the end of the quarter.